Fulgent Financial Statements From 2010 to 2026

Stocks . USA . 
Stock . Fulgent Genetics
FLGT Stock  USD 26.40  0.87  3.19%   
Analyzing historical trends in various income statement and balance sheet accounts from Fulgent Genetics' financial statements helps investors evaluate the company's valuation, profitability, and current liquidity needs. Key fundamental drivers impacting Fulgent Genetics' valuation are summarized below:
Gross Profit
130.1 M
Profit Margin
(0.14)
Market Capitalization
851 M
Enterprise Value Revenue
1.5583
Revenue
315.5 M
There are currently one hundred twenty fundamental signals for Fulgent Genetics that can be evaluated and compared over time across rivals. All traders should verify Fulgent Genetics' prevailing fundamentals against the performance from 2010 to 2026 and make sure the trends continue to evolve in the right direction.

Fulgent Genetics Total Revenue

270.77 Million

Check Fulgent Genetics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Fulgent Genetics' main balance sheet or income statement drivers, such as Discontinued Operations of 49.5 K, Depreciation And Amortization of 30.1 M or Interest Expense of 185.7 K, as well as many indicators such as Price To Sales Ratio of 2.15, Dividend Yield of 0.018 or PTB Ratio of 0.54. Fulgent financial statements analysis is a perfect complement when working with Fulgent Genetics Valuation or Volatility modules.
  
Build AI portfolio with Fulgent Stock
Check out the analysis of Fulgent Genetics Correlation against competitors.
For more information on how to buy Fulgent Stock please use our How to Invest in Fulgent Genetics guide.

Fulgent Genetics Balance Sheet

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Total Assets1.5 B1.4 B527.8 M
Slightly volatile
Other Current Liabilities27.6 M26.3 M10 M
Slightly volatile
Total Current Liabilities48.4 M83.8 M36.3 M
Slightly volatile
Total Stockholder Equity1.4 B1.3 B481.9 M
Slightly volatile
Property Plant And Equipment Net127.5 M121.4 M39.4 M
Slightly volatile
Accounts Payable11.2 M21.1 M8.5 M
Slightly volatile
Cash51.8 M63.4 M37.3 M
Slightly volatile
Non Current Assets Total1 B996.4 M313.5 M
Slightly volatile
Other Assets1.091.1558 M
Pretty Stable
Cash And Short Term Investments211.3 M296.8 M154.2 M
Slightly volatile
Net Receivables58.1 M88.6 M42.9 M
Slightly volatile
Common Stock Shares Outstanding24.9 M34.8 M22.3 M
Slightly volatile
Liabilities And Stockholders Equity1.5 B1.4 B527.8 M
Slightly volatile
Inventory4.9 M9.6 M3.8 M
Slightly volatile
Other Current Assets7.5 M11.6 M5.5 M
Slightly volatile
Other Stockholder Equity655.8 M624.6 M250.7 M
Slightly volatile
Total Liabilities56.9 M104.4 M43.1 M
Slightly volatile
Property Plant And Equipment Gross189.9 M180.8 M55.7 M
Slightly volatile
Total Current Assets280.5 M406.6 M205.6 M
Slightly volatile
Property Plant Equipment119.4 M113.8 M39.3 M
Slightly volatile
Common Stock Total Equity2.6 K2.7 K4.3 M
Slightly volatile
Common Stock2.6 K2.7 K4.3 M
Slightly volatile
Other Liabilities21.1 M20.1 M5.7 M
Slightly volatile
Short Term Investments194.9 M233.4 M132.6 M
Slightly volatile
Non Current Liabilities Total10.5 M20.6 M7 M
Slightly volatile
Capital Surpluse606.1 M577.2 M279.4 M
Slightly volatile
Long Term Investments688.7 M655.9 M210.8 M
Slightly volatile
Non Current Liabilities Other6.7 M5.7 M3.9 M
Slightly volatile
Net Invested Capital758.5 M1.3 B468.3 M
Slightly volatile
Net Working Capital372.7 M322.8 M212.7 M
Slightly volatile
Deferred Long Term Asset Charges100.8 K113.4 K123.8 K
Slightly volatile
Capital Stock3 K3.5 K2.4 K
Slightly volatile
Short and Long Term Debt Total18.8 M9.7 M9.1 M
Slightly volatile
Current Deferred Revenue24 M34.3 M11.3 M
Slightly volatile
Capital Lease Obligations7.7 M6.4 M5.2 M
Slightly volatile
Short Term Debt1.6 M1.7 M4.6 M
Slightly volatile
Short and Long Term Debt352.3 K370.8 K12.3 M
Slightly volatile

Fulgent Genetics Income Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Depreciation And Amortization30.1 M28.7 M9.2 M
Slightly volatile
Selling General Administrative106.4 M101.3 M34.5 M
Slightly volatile
Selling And Marketing Expenses43.8 M41.7 M15.5 M
Slightly volatile
Total Revenue270.8 M326 M194.7 M
Slightly volatile
Gross Profit174.3 M123.3 M120.1 M
Slightly volatile
Other Operating Expenses431.5 M411 M146.2 M
Slightly volatile
Research Development58.9 M56.1 M17.5 M
Slightly volatile
Cost Of Revenue212.8 M202.7 M81.4 M
Slightly volatile
Total Operating Expenses218.7 M208.3 M77.5 M
Slightly volatile
Interest Income38 M36.2 M8.2 M
Slightly volatile
Reconciled Depreciation30.1 M28.7 M9.9 M
Slightly volatile

Fulgent Genetics Cash Flow Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Begin Period Cash Flow117.7 M112.1 M41.2 M
Slightly volatile
Depreciation30.1 M28.7 M9.7 M
Slightly volatile
Capital Expenditures48.7 M46.4 M15 M
Slightly volatile
End Period Cash Flow51.8 M63.6 M37.3 M
Slightly volatile
Change To Netincome91.1 M86.8 M27.4 M
Slightly volatile
Stock Based Compensation53.7 M51.2 M18.2 M
Slightly volatile

Financial Ratios

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Price To Sales Ratio2.152.2740.5358
Slightly volatile
Dividend Yield0.0180.02020.0221
Slightly volatile
PTB Ratio0.540.5730.6741
Slightly volatile
Days Sales Outstanding99.1911496.8941
Pretty Stable
Book Value Per Share35.2933.6115.6213
Slightly volatile
Stock Based Compensation To Revenue0.210.180.3758
Slightly volatile
Capex To Depreciation3.31.863.1241
Pretty Stable
PB Ratio0.540.5730.6741
Slightly volatile
EV To Sales1.972.0840.3415
Slightly volatile
Inventory Turnover22.1118.9221.4732
Slightly volatile
Days Of Inventory On Hand24.9419.9729.9379
Slightly volatile
Payables Turnover6.688.647.6396
Slightly volatile
Sales General And Administrative To Revenue0.230.360.2127
Slightly volatile
Research And Ddevelopement To Revenue0.220.20.248
Slightly volatile
Capex To Revenue0.180.160.2613
Slightly volatile
Cash Per Share5.627.685.336
Slightly volatile
Days Payables Outstanding65.5743.7360.1393
Pretty Stable
Current Ratio9.025.586.5486
Slightly volatile
Tangible Book Value Per Share30.3828.9413.8225
Slightly volatile
Receivables Turnover3.663.314.1532
Slightly volatile
Shareholders Equity Per Share35.4233.7315.629
Slightly volatile
Debt To Equity0.00820.00860.0258
Slightly volatile
Capex Per Share1.261.20.5112
Slightly volatile
Graham Net Net5.386.825.0752
Slightly volatile
Revenue Per Share7.118.446.6861
Slightly volatile
Interest Debt Per Share0.460.260.4027
Slightly volatile
Debt To Assets0.00760.0080.0237
Slightly volatile
Graham Number96.7577.2576.6082
Pretty Stable
Short Term Coverage Ratios48.3146.018.1669
Slightly volatile
Operating Cycle122134126
Slightly volatile
Price Book Value Ratio0.540.5730.6741
Slightly volatile
Days Of Payables Outstanding65.5743.7360.1393
Pretty Stable
Company Equity Multiplier1.221.241.1602
Slightly volatile
Long Term Debt To Capitalization0.00270.00250.0026
Slightly volatile
Total Debt To Capitalization0.00810.00850.025
Slightly volatile
Debt Equity Ratio0.00820.00860.0258
Slightly volatile
Quick Ratio8.885.456.3745
Slightly volatile
Net Income Per E B T1.440.952.0062
Slightly volatile
Cash Ratio1.640.871.2077
Slightly volatile
Days Of Inventory Outstanding24.9419.9729.9379
Slightly volatile
Days Of Sales Outstanding99.1911496.8941
Pretty Stable
Cash Flow Coverage Ratios2.722.864.1847
Pretty Stable
Price To Book Ratio0.540.5730.6741
Slightly volatile
Fixed Asset Turnover4.182.424.0798
Slightly volatile
Debt Ratio0.00760.0080.0237
Slightly volatile
Cash Flow To Debt Ratio2.722.864.1847
Pretty Stable
Price Sales Ratio2.152.2740.5358
Slightly volatile
Asset Turnover0.250.270.5215
Slightly volatile
Gross Profit Margin0.420.340.4537
Slightly volatile
Price Fair Value0.540.5730.6741
Slightly volatile

Fulgent Fundamental Market Drivers

Forward Price Earnings7.9365
Cash And Short Term Investments258.1 M

Fulgent Upcoming Events

27th of February 2024
Upcoming Quarterly Report
View
3rd of May 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
27th of February 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View

About Fulgent Genetics Financial Statements

Fulgent Genetics shareholders use historical fundamental indicators, such as revenue or net income, to determine how well the company is positioned to perform in the future. Although Fulgent Genetics investors may analyze each financial statement separately, they are all interrelated. The changes in Fulgent Genetics' assets and liabilities, for example, are also reflected in the revenues and expenses on on Fulgent Genetics' income statement. Understanding these patterns can help investors time the market effectively. Please read more on our fundamental analysis page.
Last ReportedProjected for Next Year
Current Deferred Revenue34.3 M24 M
Total Revenue326 M270.8 M
Cost Of Revenue202.7 M212.8 M
Stock Based Compensation To Revenue 0.18  0.21 
Sales General And Administrative To Revenue 0.36  0.23 
Research And Ddevelopement To Revenue 0.20  0.22 
Capex To Revenue 0.16  0.18 
Revenue Per Share 8.44  7.11 
Ebit Per Revenue(0.23)(0.22)

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.
Explore Investing Ideas  

Additional Tools for Fulgent Stock Analysis

When running Fulgent Genetics' price analysis, check to measure Fulgent Genetics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Fulgent Genetics is operating at the current time. Most of Fulgent Genetics' value examination focuses on studying past and present price action to predict the probability of Fulgent Genetics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Fulgent Genetics' price. Additionally, you may evaluate how the addition of Fulgent Genetics to your portfolios can decrease your overall portfolio volatility.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2026 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY